hotspot -WSS

hotspot

author：fashion 2025-09-28 23:24:24 - browse：8

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How one patient went off dialysis — and others can too

WSS

Doulas covered by Medicaid under New York's new plan

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Designating disabled people as health disparity population is crucial

HHS names first

Intercept Pharmaceuticals sells itself for less than $1 billion

hotspot

hotspot

hotspot

Bright Health sells Medicare Advantage business to Molina

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Drug repurposing or repositioning? The language matters

Menendez indictment could see pharma lose a key ally

Medicare proposal to cover medical devices draws a mixed reaction

Kaiser Permanente unions announce official strike date

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Alkermes shareholders re

Readout LOUD podcast: live from JPM 2024

leisure time

Generative AI mines health records to identify patients’ social needs

Ionis has late

Medicare drug price negotiation program allowed for now

Readout LOUD podcast: live from JPM 2024

HHS names first

Menendez indictment could see pharma lose a key ally

focus

knowledge

explore

entertainment